RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pieris Pharmaceuticals Stock

Pieris Pharmaceuticals Net Income 2024

Pieris Pharmaceuticals Net Income

-269,280.02 USD

Ticker

PIRS

ISIN

US7207951036

WKN

A12G4Q

In 2024, Pieris Pharmaceuticals's profit amounted to -269,280.02 USD, a -98.9% increase from the -24.54 M USD profit recorded in the previous year.

The Pieris Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2028e-
2027e-
2026e-417.38
2025e-390.46
2024e-269.28
2023-24,543
2022-33,277
2021-45,738
2020-37,230
2019-28,299
2018-26,754
2017-17,647
2016-22,799
2015-14,059
2014-9,850
201366

Pieris Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pieris Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pieris Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pieris Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pieris Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pieris Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pieris Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pieris Pharmaceuticals’s growth potential.

Pieris Pharmaceuticals Revenue, EBIT and net profit per share

DatePieris Pharmaceuticals RevenuePieris Pharmaceuticals EBITPieris Pharmaceuticals Net Income
2028e193.39 M undefined148.1 M undefined0 undefined
2027e17.85 M undefined-42.33 M undefined0 undefined
2026e0 undefined-28.65 M undefined-417,384 undefined
2025e0 undefined-27.15 M undefined-390,456.02 undefined
2024e6.76 M undefined-22.28 M undefined-269,280.02 undefined
202342.81 M undefined-15.84 M undefined-24.54 M undefined
202225.9 M undefined-43.47 M undefined-33.28 M undefined
202131.42 M undefined-51.83 M undefined-45.74 M undefined
202029.32 M undefined-33.92 M undefined-37.23 M undefined
201946.28 M undefined-27.16 M undefined-28.3 M undefined
201829.1 M undefined-30.83 M undefined-26.75 M undefined
201725.28 M undefined-14.59 M undefined-17.65 M undefined
20165.83 M undefined-22.76 M undefined-22.8 M undefined
20152.93 M undefined-13.68 M undefined-14.06 M undefined
20145.37 M undefined-7.2 M undefined-9.85 M undefined
201312.43 M undefined554,000 undefined66,000 undefined

Pieris Pharmaceuticals stock margins

The Pieris Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pieris Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pieris Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pieris Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Pieris Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pieris Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pieris Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pieris Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pieris Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pieris Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pieris Pharmaceuticals Margin History

Pieris Pharmaceuticals Gross marginPieris Pharmaceuticals Profit marginPieris Pharmaceuticals EBIT marginPieris Pharmaceuticals Profit margin
2028e0 %76.58 %0 %
2027e0 %-237.14 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %-329.71 %-3.98 %
20230 %-37.01 %-57.33 %
20220 %-167.84 %-128.47 %
20210 %-164.97 %-145.58 %
20200 %-115.68 %-126.97 %
20190 %-58.68 %-61.15 %
20180 %-105.94 %-91.93 %
20170 %-57.74 %-69.82 %
20160 %-390.31 %-391 %
20150 %-466.61 %-479.5 %
20140 %-134.17 %-183.6 %
20130 %4.46 %0.53 %

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Pieris Pharmaceuticals's Profit Margins

The profit margins of Pieris Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Pieris Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Pieris Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Pieris Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Pieris Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Pieris Pharmaceuticals stock

How much profit has Pieris Pharmaceuticals made this year?

Pieris Pharmaceuticals has made -269,280.02 USD this year.

How has the profit developed compared to last year?

The profit has increased by -98.9% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Pieris Pharmaceuticals publish its earnings?

Pieris Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Pieris Pharmaceuticals?

The profits of Pieris Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Pieris Pharmaceuticals?

You can learn more about the earnings of Pieris Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pieris Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pieris Pharmaceuticals

Our stock analysis for Pieris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pieris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.